RVTYRevvity
Price
+76%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, no red flags, demanding price, growth fading, the market undecided.
We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. As of December 28, 2025, we employed approximately 11,000 employees.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Revvity (RVTY) reported revenue of $730M in Q2 2026 (quarter ended Jul 5, 2026), up 1.3% from the same quarter a year earlier. That came with a gross margin of 57% and net income of $52M (7.1% of revenue). For the full year FY2025, revenue was $2.86B (+3.7% year on year) and net income $241M. Its largest segment in Q2 2026 was Life Sciences at $184M, 56% of the disclosed total, ahead of Diagnostics at 44%. The next results filing is expected around Oct 26, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026The agreement provides for the sale of China IDX for up to $200 million, subject to adjustments and satisfaction of conditions. Management believes it is probable the transaction will close by the end of 2027 and therefore has included the unaudited pro forma condensed consolidated financial statements herein.Earnings release · Form 8-K
- May 5, 2026The letter of intent provided for the sale of China IDX for up to $200 million, subject to adjustments and satisfaction of conditions. Management believes it is probable the transaction will close in 2027 and therefore has included the unaudited pro forma condensed consolidated financial statements herein.Earnings release · Form 8-K
- May 1, 2026Amendments to Articles of Organization or Bylaws; Change in Fiscal Year At the annual meeting of shareholders of Revvity, Inc. (the “Company”) held on April 28, 2026, the shareholders voted on and approved a proposal to amend the Company’s Amended and Restated By-laws (prior to such amendment and restatement, the …Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $325.6MThe company’s own SEC segment disclosure.
- Life Sciences$183.6M56%
- Diagnostics$142.0M44%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
The closest names by size in the same industry